Biospecimen and Pathology Core

项目总结-生物标本和病理学核心B Wistar/UPenn SPORE皮肤癌生物标本和病理学核心的主要目标是 提供一个集中的设施，重点是采购、处理、分析和分发恶性和 正常组织，以支持转化癌症研究，特别是黑色素瘤研究。核心已经 在前一个资助期内，所有SPORE项目的有效资源，这些项目严重依赖组织， 并将继续为推进拟议的SPORE项目提供必要的支持服务。的 核心将收集、储存和处理高质量和注释良好的生物标本（血液、新鲜和石蜡 使用以项目特定方式修改的SOP（目标1），对肿瘤和正常组织进行组织学检查（包埋组织）。我们将 扩展和维护功能性多机构综合生物标本和临床数据库，包括 病理、治疗、复发和随访数据以及全面的采集和分发 与组织使用相关的数据。现有的数据库支持水平、垂直和跨 SPORE合作（目标2）。我们将选择和分发高质量的生物标本。我们已经开发 从良性、原发性和转移性肿瘤中选择、制备和分发注释良好的组织的程序; 根据每个项目的规范，从生物标本中提取DNA、RNA和蛋白质。分布 由组织资源分配委员会（TRAC）制定的指导方针管理，以确保有效和 最大限度地利用组织和患者保密性（目标3）。我们将提供所有的组织学检查 每个项目使用的生物标本，组织处理和免疫组织化学，以及专家对 对组织进行的研究（目标4）。最后，我们将开发创新的研究分析和组织 满足每个项目具体需求的准备方法，并促进临床影响力研究 (Aim 5）。

Project Summary – Biospecimen and Pathology Core B The primary objective of the Biospecimen and Pathology Core of the Wistar/UPenn SPORE in Skin Cancer is to provide a centralized facility focused on procurement, processing, analysis and distribution of malignant and normal tissue in support of translational cancer research, particularly melanoma research. The Core has been an effective resource for all SPORE projects in the prior funding period, which were heavily tissue-dependent, and will continue to provide essential support services for the proposed SPORE Projects moving forward. The Core will collect, store and process high-quality and well-annotated biospecimens (blood, fresh and paraffin embedded tissue) of tumor and normal tissue using SOPs modified in a Project specific manner (Aim 1). We will expand and maintain a functional multi-institutional integrated biospecimen and clinical database that includes pathological, treatment, recurrence, and follow-up data as well as comprehensive acquisition and distribution data associated with the use of tissue. The already existing database supports horizontal, vertical and inter- SPORE collaborations (Aim 2). We will select and distribute high quality biospecimens. We have developed procedures to select, prepare and distribute well-annotated tissues from benign, primary and metastatic tumors; DNA, RNA and proteins from biospecimens according to the specifications of each project. Distribution is governed by guidelines developed by the Tissue Resource Allocation Committee (TRAC) to ensure efficient and maximal use of tissue, and patient confidentiality (Aim 3). We will provide histological examination of all biospecimens used by each project, tissue processing and immunohistochemistry, and expert interpretation of studies performed on the tissue (Aim 4). Finally, we will develop innovative research assays and tissue preparation methods catering to the specific needs of each project and to facilitate clinically impactful research (Aim 5).